Clinical Pharmacology in Drug Development

Scope & Guideline

Empowering professionals with cutting-edge pharmacological insights.

Introduction

Explore the comprehensive scope of Clinical Pharmacology in Drug Development through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Clinical Pharmacology in Drug Development in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2160-7648
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2012 to 2024
AbbreviationCLIN PHARM DRUG DEV / Clin. Pharmacol. Drug Dev.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Clinical Pharmacology in Drug Development' focuses on advancing the field of clinical pharmacology, particularly through the evaluation of drug pharmacokinetics, bioequivalence, safety, and efficacy in various populations. It emphasizes studies that contribute to drug development processes and regulatory science, with a strong emphasis on methodological rigor and innovative approaches.
  1. Pharmacokinetics and Pharmacodynamics:
    Research that explores the absorption, distribution, metabolism, and excretion of drugs, alongside their biological effects, is a core focus. This includes studies on drug-drug interactions and the impact of genetic factors on drug response.
  2. Bioequivalence Studies:
    The journal frequently publishes studies assessing the bioequivalence of generic and branded drugs, which are critical for regulatory approvals and market access.
  3. Safety and Tolerability Assessments:
    A significant portion of the research is dedicated to evaluating the safety profiles of new drugs, including adverse effects and tolerability in diverse populations.
  4. Population Pharmacokinetics:
    Studies that utilize population pharmacokinetic modeling to analyze drug behavior in specific patient groups, including those with comorbidities or differing ethnic backgrounds, are highlighted to enhance personalized medicine.
  5. Phase I Clinical Trials:
    The journal emphasizes research from Phase I trials, which are essential for understanding the initial safety, tolerability, and pharmacokinetic profiles of new therapeutic agents.
  6. Innovative Drug Development Methodologies:
    The journal encourages submissions that explore new methodologies in drug development, including model-informed approaches and adaptive trial designs.
The journal has witnessed emerging themes that reflect the evolving landscape of drug development and clinical pharmacology. These trends indicate a shift towards precision medicine and innovative therapeutic strategies.
  1. Personalized Medicine Approaches:
    There is an increasing emphasis on studies that explore personalized medicine, particularly how individual genetic makeup influences drug response and safety, reflecting a broader trend in healthcare towards tailored therapies.
  2. Innovations in Drug Delivery Systems:
    Research focusing on novel drug delivery systems, including sustained-release formulations and targeted delivery mechanisms, has gained traction, highlighting advancements in improving drug efficacy and patient compliance.
  3. Real-World Evidence and Post-Marketing Surveillance:
    The journal is increasingly publishing studies that utilize real-world evidence to assess drug performance post-approval, emphasizing the importance of understanding drug effects in everyday clinical practice.
  4. Complex Drug Interactions:
    The complexity of drug-drug interactions, especially involving polypharmacy in older populations or patients with comorbid conditions, is becoming a more prominent area of research, reflecting the realities of modern healthcare.
  5. Evolving Regulatory Science:
    There is a growing interest in the regulatory aspects of drug development, including submissions that discuss the implications of new regulations on clinical trial designs and drug approval processes.

Declining or Waning

While the journal maintains a strong focus on pharmacokinetics and drug development, certain areas of research have seen a reduction in prominence over recent years, reflecting shifts in scientific interest and regulatory priorities.
  1. Traditional Drug Formulations:
    There has been a noticeable decline in studies focused solely on traditional drug formulations without considering innovative delivery systems or combinations. The shift towards more complex formulations and combination therapies is evident.
  2. Non-Clinical Studies:
    Research that primarily focuses on non-clinical or preclinical studies has decreased, as the journal emphasizes clinical data and results from human trials.
  3. Fixed-Dose Combinations without Novel Insights:
    Publications that discuss fixed-dose combinations without providing new insights into their pharmacokinetic profiles or novel therapeutic outcomes have become less frequent, as the field moves towards more innovative combinations.
  4. Pharmacogenomics Studies:
    Although pharmacogenomics remains important, the specific focus on genetic polymorphisms affecting pharmacokinetics has seen a decline, possibly due to the broader integration of such analyses into standard pharmacokinetic studies.

Similar Journals

CLINICAL PHARMACOLOGY & THERAPEUTICS

Transforming research into practice in clinical pharmacology.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

European Journal of Pharmacology

Shaping the future of pharmacology through impactful scholarship.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

CLINICAL PHARMACOKINETICS

Advancing the Science of Drug Metabolism
Publisher: ADIS INT LTDISSN: 0312-5963Frequency: 12 issues/year

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

CPT-Pharmacometrics & Systems Pharmacology

Innovating the landscape of pharmacometrics for better health outcomes.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.

Journal of Pharmaceutical Health Care and Sciences

Catalyzing advancements in healthcare through rigorous research.
Publisher: BMCISSN: 2055-0294Frequency: 1 issue/year

The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.

DRUG METABOLISM REVIEWS

Connecting scholars to the forefront of drug science.
Publisher: TAYLOR & FRANCIS LTDISSN: 0360-2532Frequency: 4 issues/year

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

FARMACIA

Connecting Researchers to the Pulse of Pharmaceutical Innovation.
Publisher: SOC STIINTE FARMACEUTICE ROMANIAISSN: 0014-8237Frequency: 6 issues/year

FARMACIA is a renowned academic journal published by the SOC STIINTE FARMACEUTICE ROMANIA, specializing in the field of pharmacology, toxicology, and pharmaceutics. With a rich history dating back to its initial publication years of 1945 to 1946, and ongoing contributions since 2008, the journal has established itself as a significant platform for disseminating cutting-edge research in the pharmaceutical sciences. Indexed in Scopus, it holds a commendable Q2 ranking in the Pharmacology, Toxicology and Pharmaceutics category, reflecting its importance in the field. The journal aims to foster knowledge sharing and innovation among researchers, professionals, and students alike, making it an essential resource for advancing pharmaceutical research. Although it does not currently offer Open Access, the content is accessible to a broad academic audience, ensuring valuable insights into current trends and discoveries in pharmacotherapy and drug development. For those seeking a deeper understanding of the evolving landscape of pharmaceutical sciences, FARMACIA provides a critical lens through which to explore and engage with the latest scientific advancements.

DRUG METABOLISM AND DISPOSITION

Fostering Excellence in Pharmacology and Toxicology
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Leading the Charge in Medical Pharmacology Advancements
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Pioneering Discoveries in Biological and Pharmaceutical Research
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.